Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States
- DOI
- 10.1016/j.lungcan.2026.109586
- Published
- 2026-10
- Container
- Lung Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2026.109586,
title = {Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States},
author = {Jhanelle E. Gray and Kelli Thoele and Madeline Richey and Nada Boualam and Karen Schwed and Erich Brechtelsbauer and Qinli Ma and Kristin M. Sheffield},
year = {2026},
journal = {Lung Cancer},
doi = {10.1016/j.lungcan.2026.109586},
url = {https://doi.org/10.1016/j.lungcan.2026.109586}
}RIS
TY - JOUR TI - Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States AU - Jhanelle E. Gray AU - Kelli Thoele AU - Madeline Richey AU - Nada Boualam AU - Karen Schwed AU - Erich Brechtelsbauer AU - Qinli Ma AU - Kristin M. Sheffield PY - 2026 JO - Lung Cancer DO - 10.1016/j.lungcan.2026.109586 UR - https://doi.org/10.1016/j.lungcan.2026.109586 ER -
APA
Gray, J. E., Thoele, K., Richey, M., Boualam, N., Schwed, K., Brechtelsbauer, E., Ma, Q., & Sheffield, K. M. (2026). Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109586
Source records
- crossref · retrieved 2026-09-27T01:13:33.584Z